Myers' upcoming $30B patent cliff as the Growth portfolio lost significant potential. Read why BMY stock is downgraded to ...

Individual-level attribution modeling reveals that real-world semaglutide effectiveness is not a fixed property of the molecule, but an interaction between pharmacological exposure and modifiable care ...

The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?

BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.

US$46 million investment to establish wholly owned Puerto Rico subsidiary supporting U.S. manufacturing, supply security, and long-term growth of BESREMi (R) (ropeginterferon alfa-2b) Company plans to ...

Bacteria incubated with bacteriophages in space accumulated distinct mutations compared to those on Earth, highlighting the ...

Here’s some spine-tingling news. New research suggests a drug already available on pharmacy shelves could help ease chronic ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript February 11, 2026 Viking Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.38 EPS, expectations were $-0.

Portal designs often amplify alarm rather than offering context ...

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...

Some human research will no longer be classified as a clinical trial, easing the paperwork burden, but not everyone agrees with the approach.